Publications by authors named "J Gorodkin"

Patents are essential for transferring scientific discoveries to meaningful products that benefit societies. While the academic community focuses on the number of citations to rank scholarly works according to their "scientific merit," the number of citations is unrelated to the relevance for patentable innovation. To explore associations between patents and scholarly works in publicly available patent data, we propose to utilize statistical methods that are commonly used in biology to determine gene-disease associations.

View Article and Find Full Text PDF

RNA secondary structures play essential roles in the formation of the tertiary structure and function of a transcript. Recent genome-wide studies highlight significant potential for RNA structures in the mammalian genome. However, a major challenge is assigning functional roles to these structured RNAs.

View Article and Find Full Text PDF

Introduction: Chimeric antigen receptor-expressing T cells (CAR T cells) have revolutionized cancer treatment, particularly in B cell malignancies. However, the use of autologous T cells for CAR T therapy presents several limitations, including high costs, variable efficacy, and adverse effects linked to cell phenotype.

Methods: To overcome these challenges, we developed a strategy to generate universal and safe anti-CD19 CAR T cells with a defined memory phenotype.

View Article and Find Full Text PDF

Over the last quarter of a century it has become clear that RNA is much more than just a boring intermediate in protein expression. Ancient RNAs still appear in the core information metabolism and comprise a surprisingly large component in bacterial gene regulation. A common theme with these types of mostly small RNAs is their reliance of conserved secondary structures.

View Article and Find Full Text PDF
Article Synopsis
  • - COST (European Cooperation in Science and Technology) funds and coordinates scientific research in Europe, recently supporting the "Genome Editing to treat Human Diseases" (GenE-HumDi) network that connects various stakeholders including pharmaceutical companies and academia.
  • - GenE-HumDi’s main goal is to fast-track the use of genome editing for treating human diseases through organized working groups that improve technologies, assess safety, and create regulatory guidelines.
  • - The initiative aims to standardize practices, share knowledge, and effectively communicate the potential of genome editing to the public, highlighted by their first meeting in March 2023 in Granada, Spain.
View Article and Find Full Text PDF